CD13 as a potential membrane marker in PSMA-negative prostate cancer and first-in-human study of [18F]AlF-CD13-L1 PET/CT imaging

被引:0
|
作者
Tang, W. [1 ]
Zhou, M. [2 ]
Lu, C. [2 ]
Qi, L. [1 ]
Zhang, Y. [3 ]
Tang, Y. [2 ]
Gao, X. [4 ]
Hu, S. [2 ]
Cai, Y. [1 ]
机构
[1] Cent South Univ, Xiangya Hosp, Urol, Changsha, Peoples R China
[2] Cent South Univ, Xiangya Hosp, Nucl Med, Changsha, Peoples R China
[3] Cent South Univ, Xiangya Hosp, Oncol, Changsha, Peoples R China
[4] Cent South Univ, Xiangya Hosp, Pathol, Changsha, Peoples R China
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
D O I
10.1016/j.annonc.2024.10.378
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
359P
引用
收藏
页数:2
相关论文
共 32 条
  • [31] [18F]-piflufolastat used for PSMA-PET/CT imaging of patients presenting with first biochemical recurrence of prostate cancer: assessment of the agreement of per-region reading between an experienced nuclear medicine physician and a deep-learning-based software
    Gauthe, M.
    Richter, J.
    Balogova, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S342 - S342
  • [32] A phase 1 first-in-human study of interferon beta (IFNb) and membrane-stable CD40L expressing oncolytic virus (MEM-288) in solid tumors including non-small-cell lung cancer (NSCLC)
    Saltos, Andreas Nicholas
    Arrowood, Christy
    Beasley, Georgia
    Ronald, James
    El-Haddad, Ghassan
    Guerra-Guevara, Luiziane
    Khan, Uzma
    Wolf, Steven
    Gu, Lin
    Wang, Xiaofei F.
    Foresman, Dana
    Yu, Xiaoqing
    Cantwell, Mark J.
    Antonia, Scott Joseph
    Beg, Amer A.
    Ready, Neal E.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)